Safety and Efficacy of ADAPTAVIR's Ability to Eliminate Treatment-Resistant Infectious Virus in the Blood Cellular Reservoir (PBMCs) of HIV Patients With Suppressed Plasma Viral Load.
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs DAPTA (Primary)
- Indications HIV infections
- Focus Adverse reactions
- 21 Mar 2011 Status changed from recruiting to completed, as reported in a RAPID Pharmaceuticals media release.
- 07 Aug 2009 New trial record